A detailed history of Banco Santander, S.A. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Banco Santander, S.A. holds 15,868 shares of VRTX stock, worth $7.43 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
15,868
Previous 16,428 3.41%
Holding current value
$7.43 Million
Previous $7.7 Million 4.17%
% of portfolio
0.09%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$460.0 - $505.78 $257,600 - $283,236
-560 Reduced 3.41%
15,868 $7.38 Million
Q2 2024

Jul 29, 2024

SELL
$392.81 - $485.53 $206,225 - $254,903
-525 Reduced 3.1%
16,428 $7.7 Million
Q1 2024

May 10, 2024

SELL
$407.69 - $446.08 $1.4 Million - $1.54 Million
-3,442 Reduced 16.88%
16,953 $7.09 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $740,880 - $887,068
-2,160 Reduced 9.58%
20,395 $8.3 Million
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $463,306 - $496,570
-1,370 Reduced 5.73%
22,555 $7.84 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $1.74 Million - $1.95 Million
-5,530 Reduced 18.77%
23,925 $8.42 Million
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $2.23 Million - $2.55 Million
-7,880 Reduced 21.11%
29,455 $9.28 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $1.18 Million - $1.33 Million
-4,135 Reduced 9.97%
37,335 $10.8 Million
Q3 2022

Nov 08, 2022

SELL
$273.83 - $305.53 $314,904 - $351,359
-1,150 Reduced 2.7%
41,470 $12 Million
Q2 2022

Jul 28, 2022

SELL
$234.96 - $292.55 $2.95 Million - $3.68 Million
-12,572 Reduced 22.78%
42,620 $12 Million
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $1.76 Million - $2.07 Million
7,930 Added 16.78%
55,192 $14.4 Million
Q4 2021

Feb 09, 2022

BUY
$177.01 - $223.45 $230,113 - $290,485
1,300 Added 2.83%
47,262 $10.4 Million
Q3 2021

Nov 08, 2021

BUY
$181.39 - $202.99 $7.81 Million - $8.73 Million
43,030 Added 1467.6%
45,962 $8.34 Million
Q2 2021

Jul 29, 2021

SELL
$187.49 - $221.1 $248,236 - $292,736
-1,324 Reduced 31.11%
2,932 $591,000
Q1 2021

May 10, 2021

BUY
$207.02 - $241.31 $73,906 - $86,147
357 Added 9.16%
4,256 $914,000
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $3.03 Million - $4.04 Million
-14,622 Reduced 78.95%
3,899 $921,000
Q3 2020

Nov 09, 2020

SELL
$255.65 - $303.1 $27.5 Million - $32.6 Million
-107,431 Reduced 85.3%
18,521 $5.04 Million
Q2 2020

Aug 05, 2020

SELL
$225.48 - $295.8 $10.9 Million - $14.3 Million
-48,443 Reduced 27.78%
125,952 $36.6 Million
Q1 2020

May 11, 2020

BUY
$199.77 - $247.81 $15 Million - $18.6 Million
74,906 Added 75.29%
174,395 $41.5 Million
Q4 2019

Feb 07, 2020

BUY
$166.71 - $223.91 $12.7 Million - $17 Million
75,993 Added 323.43%
99,489 $21.8 Million
Q3 2019

Nov 06, 2019

SELL
$166.23 - $187.09 $15.8 Million - $17.8 Million
-95,083 Reduced 80.19%
23,496 $3.98 Million
Q2 2019

Aug 07, 2019

SELL
$164.61 - $190.37 $38.8 Million - $44.9 Million
-235,594 Reduced 66.52%
118,579 $21.7 Million
Q1 2019

May 13, 2019

SELL
$163.73 - $194.7 $147,029 - $174,840
-898 Reduced 0.25%
354,173 $65.2 Million
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $16,254 - $20,566
-107 Reduced 0.03%
355,071 $58.8 Million
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $322,712 - $370,831
1,924 Added 0.54%
355,178 $68.5 Million
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $2.01 Million - $2.35 Million
13,799 Added 4.07%
353,254 $60 Million
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $402,498 - $470,280
2,655 Added 0.79%
339,455 $55.3 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $1.35 Million - $1.52 Million
9,800 Added 3.0%
336,800 $50.5 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $48.4 Million - $53.1 Million
327,000
327,000 $49.7 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Banco Santander, S.A. Portfolio

Follow Banco Santander, S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banco Santander, S.A., based on Form 13F filings with the SEC.

News

Stay updated on Banco Santander, S.A. with notifications on news.